Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Sham Injection Clear all
Completed Phase 4 Interventional Results available

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 21, 2026, 4:58 AM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

NCT01049919
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
Bone marrow concentration device, Placebo procedure (sham)
Device · Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
25
States / cities
Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 21, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Not applicable Interventional

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

NCT05053503
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Device · Drug
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rancho Mirage, California • Crownsville, Maryland • Center City, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Not applicable Interventional

Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis

NCT01713959
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Ulthera System treatment, Sham treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 21, 2026, 4:58 AM EDT
Recruiting Phase 2 Interventional

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

NCT07812090
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

NCT02050828
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
AKB-9778, ranibizumab, Placebo, Sham
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Pheonix, Arizona • Tucson, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 21, 2026, 4:58 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

NCT03645408
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Exenatide, Sham injection
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950
View directory record Official record
Conditions
Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions
LFG316, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 21, 2026, 4:58 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Early BOTOX After Spinal Cord Injury

NCT06793683
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Bladder chemodenervation (Botox), Bladder Sham (Saline) Injection Procedure
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

NCT06270836
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Tarcocimab, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 21, 2026, 4:58 AM EDT
Terminated Not applicable Interventional Results available

Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

NCT02161484
View directory record Official record
Conditions
Osteoarthritis of Hip, Regional Anesthesia, Other Acute Postoperative Pain, Total Hip Arthroplasty, Peripheral Nerve Block, Lumbar Plexus Nerve Block, Parasacaral (Sciatic) Nerve Block
Interventions
Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%
Procedure · Drug
Lead sponsor
Rita Merman
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

NCT01169103
View directory record Official record
Conditions
Obesity
Interventions
recombinant human growth hormone (rhGH), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

NCT04238598
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Pulse Radiofrequency, Standard of Care Intra- Articular Injection, Placebo Intra-Articular Injection
Procedure
Lead sponsor
Center For Interventional Pain and Spine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Exton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 21, 2026, 4:58 AM EDT
Recruiting Phase 2 Interventional

Lidocaine Patch vs Intradermal Lidocaine for Epidural Needle Insertion Pain

NCT07700108
View directory record Official record
Conditions
Needle Phobia
Interventions
Lidocaine patch 4%
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 21, 2026, 4:58 AM EDT
Recruiting Phase 2 Interventional

Local Anesthesia for Facial Fractures

NCT06429501
View directory record Official record
Conditions
Pain Management
Interventions
Bupivacaine/Epinephrine, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 21, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional

Investigation of Neural Stem Cells in Ischemic Stroke

NCT03629275
View directory record Official record
Conditions
Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
Interventions
CTX0E03 Drug Product and delivery device, Placebo
Combination Product · Drug
Lead sponsor
ReNeuron Limited
Industry
Eligibility
35 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Spinal Cord Injury Rehabilitation Interventions by Retraining the Brain With Stimulation

NCT01539109
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Rehabilitation, Noninvasive brain stimulation: tDCS, Sham tDCS: placebo noninvasive brain stimulation
Behavioral · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Results available

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

NCT03662334
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
Drug · Device
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Octreotide in Severe Polycystic Liver Disease

NCT00426153
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 21, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

NCT02394028
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 21, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
400 µg Brimonidine Implant, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
55 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 21, 2026, 4:58 AM EDT